Charles Schwab’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,481
| Closed | -$46.1K | – | 3523 |
|
|
2024
Q3 | $46.1K | Sell |
2,481
-12,500
| -83% | -$232K | ﹤0.01% | 3421 |
|
|
2024
Q2 | $249K | Sell |
14,981
-5,055
| -25% | -$84.1K | ﹤0.01% | 3406 |
|
|
2024
Q1 | $348K | Sell |
20,036
-652
| -3% | -$11.3K | ﹤0.01% | 3142 |
|
|
2023
Q4 | $323K | Buy |
20,688
+2,741
| +15% | +$42.9K | ﹤0.01% | 3204 |
|
|
2023
Q3 | $887K | Buy |
17,947
+3,561
| +25% | +$176K | ﹤0.01% | 2839 |
|
|
2023
Q2 | $1.12M | Buy |
14,386
+1,160
| +9% | +$90.7K | ﹤0.01% | 2726 |
|
|
2023
Q1 | $1.2M | Buy |
13,226
+32
| +0.2% | +$2.9K | ﹤0.01% | 2680 |
|
|
2022
Q4 | $1.56M | Buy |
13,194
+191
| +1% | +$22.5K | ﹤0.01% | 2635 |
|
|
2022
Q3 | $2.36M | Buy |
13,003
+3,519
| +37% | +$639K | ﹤0.01% | 2538 |
|
|
2022
Q2 | $851K | Buy |
9,484
+566
| +6% | +$50.8K | ﹤0.01% | 2854 |
|
|
2022
Q1 | $1.39M | Sell |
8,918
-144
| -2% | -$22.4K | ﹤0.01% | 2751 |
|
|
2021
Q4 | $2.7M | Buy |
9,062
+186
| +2% | +$55.4K | ﹤0.01% | 2599 |
|
|
2021
Q3 | $5.12M | Buy |
8,876
+2,693
| +44% | +$1.55M | ﹤0.01% | 2365 |
|
|
2021
Q2 | $2.81M | Sell |
6,183
-32
| -0.5% | -$14.5K | ﹤0.01% | 2607 |
|
|
2021
Q1 | $3.35M | Buy |
6,215
+1,286
| +26% | +$692K | ﹤0.01% | 2490 |
|
|
2020
Q4 | $4.36M | Buy |
4,929
+171
| +4% | +$151K | ﹤0.01% | 2288 |
|
|
2020
Q3 | $3.01M | Buy |
+4,758
| New | +$3.01M | ﹤0.01% | 2326 |
|